ADC Sequencing in mTNBC: What Do You Do After Progression?

Category - Triple Negative

Biomarkers and Resistance: Interpreting Trop-2 ADC Performance in Diverse mTNBC Patient Subsets

How Clinicians Choose Between TROP2 ADCs

Trop−2 ADC Safety Profile: A Head-to-Head Comparison of Key AEs and Management

Endpoints and Heterogeneity: A Critical Look at PFS and OS in TROPION−Breast02 and ASCENT−03

Response Rate & Risk Profile: Interpreting Early Efficacy in High-Risk mTNBC Patients

Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC